AZD0486

DRUG7 trials

Conditions

B-Cell Acute Lymphoblastic LeukaemiaB-cell Acute Lymphoblastic Leukemia (B-ALL)B-cell Non-Hodgkin LymphomaChronic Lymphocytic LeukaemiaLarge B-Cell LymphomaLarge B-cell LymphomaMantle Cell LymphomaMantle-cell Lymphoma

Phase 1

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

RecruitingNCT06137118

AstraZenecaB-cell Acute Lymphoblastic Leukemia (B-ALL)

Start: 2023-12-29End: 2027-06-29Target: 163Updated: 2026-01-16

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia

RecruitingCTIS2023-505840-20-00

Astrazeneca ABB-Cell Acute Lymphoblastic Leukaemia

Start: 2024-08-16Target: 69Updated: 2026-01-22

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

RecruitingNCT06564038

AstraZenecaB-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Large B-cell Lymphoma +2

Start: 2025-01-30End: 2028-02-28Target: 276Updated: 2026-02-05

A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination with Other Anticancer Agents in Participants with Mature B-Cell Malignancies Substudy 1: Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma Substudy 2: Mantle Cell Lymphoma Substudy 3: Large B-Cell Lymphoma

RecruitingCTIS2024-515034-33-00

AstraZeneca ABChronic Lymphocytic Leukaemia, Large B-Cell Lymphoma, Mantle Cell Lymphoma +1

Start: 2025-03-05Target: 200Updated: 2025-11-25

Phase 2

A Modular Phase II, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B) )

RecruitingCTIS2023-505789-27-00

Astrazeneca ABRelapsed or Refractory Non-Hodgkin Lymphoma

Start: 2025-04-14Target: 73Updated: 2025-12-01

Phase 3

AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

RecruitingNCT07215585

AstraZenecaLarge B-cell Lymphoma

Start: 2025-11-11End: 2033-07-28Target: 420Updated: 2026-03-20

A Phase III, Multicentre, Open-Label, Randomised Study Evaluating the Efficacy and Safety of R-mini-CHOP x2 followed by AZD0486 versus R-mini-CHOP x6 in Elderly or Unfit Participants with Newly Diagnosed Large B-cell Lymphoma (SOUNDTRACK-D2)

Not yet recruitingCTIS2025-522029-37-00

AstraZeneca ABLarge B-cell Lymphoma

Target: 14Updated: 2026-01-30

Related Papers

Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated Results from the Phase 1/2 SYRUS study

Blood2025-11-03

SOUNDTRACK-E: A phase 1/2, open-label, multicenter study to evaluate the safety and efficacy of AZD0486 monotherapy or combination therapy in patients with mature B-cell malignancies.